ReviewOncoTargets and therapy2016
Prognostic value of endocan expression in cancers: evidence from meta-analysis.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses.Systematic reviews · 2025Pooled it
- The Role of Endocan Expression in the Diagnosis and Grading of Precancerous Gastric Lesions.Diagnostics (Basel, Switzerland) · 2025Article
- Association of plasma endocan levels with metabolic parameters and predictive value of endocan for the development of complications in patients with type 2 diabetes mellitus: An observational study.Biomolecules & biomedicine · 2025Observational
- Endocan as a biomarker for acute respiratory distress syndrome: A systematic review and meta-analysis.Health science reports · 2024Review
- B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4NPJ precision oncology · 2024Article
- Roles of endothelial cell specific molecule‑1 in tumor angiogenesis (Review).Oncology letters · 2024Review
- Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production.Frontiers in immunology · 2024Article
- Endocan, a novel glycoprotein with multiple biological activities, may play important roles in neurological diseases.Frontiers in aging neuroscience · 2024Review
- Article
- Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2023Article
- Expression of the angiogenesis markers endocan in Cushing's syndrome due to cortisol producing adenoma.Endocrine · 2023Article
- Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?Frontiers in oncology · 2023Review
- Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.Biomolecules · 2022Review
- The impact of macrophages on endothelial cells is potentiated by cycling hypoxia: Enhanced tumor inflammation and metastasis.Frontiers in oncology · 2022Article
- Prognostic and Diagnostic Value of Endocan in Kidney Diseases.International journal of nephrology · 2022Review
- Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan.Journal of inflammation (London, England) · 2020Article
- Protein Expression in Tonsillar and Base of Tongue Cancer and in Relation to Human Papillomavirus (HPV) and Clinical Outcome.International journal of molecular sciences · 2018Article
- Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.Oncotarget · 2017Article
- Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression.International journal of medical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocan is a 50 kDa dermatan sulfate proteoglycan. Numerous previous studies have indicated that endocan might be an attractive prognostic tumor biomarker. However, the results of different studies are inconsistent. We conducted a meta-analysis to explore the association between endocan expression and cancer prognosis. A systematic, comprehensive search of the PubMed, Embase, and China National Knowledge Infrastructure databases was performed. Expression of endocan and its association with overall survival were evaluated by pooled hazard ratios (HRs) and their 95% confidence intervals (CIs). In total, 15 eligible studies of 1,464 patients were finally included in this meta-analysis. A significant association was found between elevated endocan expression and poorer overall survival (pooled HR: 2.48, 95% CI: 2.12-2.90,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.